BrightGene Bio-Medical Technology Co Ltd
SSE:688166
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
20.3
39.25
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
BrightGene Bio-Medical Technology Co Ltd
BrightGene Bio-Medical Technology Co Ltd
Other Current Assets
BrightGene Bio-Medical Technology Co Ltd
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BrightGene Bio-Medical Technology Co Ltd
SSE:688166
|
Other Current Assets
¥91.8m
|
CAGR 3-Years
34%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Other Current Assets
¥129.8m
|
CAGR 3-Years
30%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Other Current Assets
¥357.3m
|
CAGR 3-Years
8%
|
CAGR 5-Years
15%
|
CAGR 10-Years
28%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Other Current Assets
¥1.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
23%
|
CAGR 10-Years
24%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Other Current Assets
¥1B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
12%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Other Current Assets
¥70.3m
|
CAGR 3-Years
58%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
BrightGene Bio-Medical Technology Co Ltd
Glance View
BrightGene Bio-Medical Technology Co., Ltd. emerges as a compelling player in the pharmaceutical landscape, weaving innovation with strategic execution. Specializing in the research, development, and manufacturing of high-quality generic drugs and pharmaceutical intermediates, the company finds its niche at the intersection of science and commerce. Founded with a vision to leverage cutting-edge technologies for developing advanced therapeutic solutions, BrightGene has carved a significant space in both domestic and international markets. Its state-of-the-art facilities reflect a commitment to rigorous quality standards and continual improvement, aligning with its mission to deliver cost-effective healthcare solutions. At the heart of BrightGene's business model is its robust pipeline of generic pharmaceutical products, which it advances from concept to commercialization. The company monetizes its innovations by licensing and supplying active pharmaceutical ingredients (APIs) and finished dosage forms to global partners, including major pharmaceutical companies. This collaborative approach ensures a steady flow of revenue through licensing agreements and joint ventures, positioning BrightGene as not just a manufacturer, but a valued partner in the quest for affordable healthcare. By continuously expanding its product portfolio and refining manufacturing processes, BrightGene sustains its growth trajectory, capitalizing on a market hungry for cost-efficient, high-quality generic medications.
See Also
What is BrightGene Bio-Medical Technology Co Ltd's Other Current Assets?
Other Current Assets
91.8m
CNY
Based on the financial report for Dec 31, 2023, BrightGene Bio-Medical Technology Co Ltd's Other Current Assets amounts to 91.8m CNY.
What is BrightGene Bio-Medical Technology Co Ltd's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
46%
Over the last year, the Other Current Assets growth was 9%. The average annual Other Current Assets growth rates for BrightGene Bio-Medical Technology Co Ltd have been 34% over the past three years , 46% over the past five years .
You don't have any saved screeners yet